Design of Potent and Selective EGFR Inhibitors against L858R/T790M Resistance Mutation

Through a 3D conformer based scaffold hopping protocol based on previously reported mutant-selective EGFR inhibitorswe designed and synthesized a series of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as novel potent and selective EGFRL858R/T790M inhibitors. For three compounds (20b20c and 20g) in this series, our design strategy to occupy S2 pocket boosts the inhibitions against double-mutant EGFR and brings the IC50 to a subnanomolar level. After three round SAR explorations, one of the most promising compounds 20g shows a favorable selectivity at both in vitro and in vivo levels, indicating that compound 20g might be used as a promising drug candidate to overcome EGFRL858R/T790M drug-resistance mutation. Further evaluation for the candidate compound is still ongoing, and will be reported in due course.

 

User Login


Database


PTID

Contact us


Honglin Li's Lab
Shanghai Key Laboratory of New Drug Design
School of Pharmacy
East China University of Sci. & Tech.
Room 527, Building 18, 130 Meilong Road,
Shanghai, 200237, P. R. China
Tel: (86) 21 6425 0213
Prof. Honglin Li
hlli@ecust.edu.cn

Copyright © 2019 Prof. HongLin Li's Group, School of Pharmacy, East China University of Science & Technology · All Right Reserved.
沪ICP备19004698号-1 |  沪公网安备31011302004713号